| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $81.4M | +4.3% |
| SG&A Expense | $42.1M | +68.0% |
| Operating Income | -$123.5M | -19.7% |
| Pre-tax Income | -$118.8M | -23.9% |
| Income Tax | $0 | -100.0% |
| Net Income | -$118.8M | -23.9% |
| EPS (Basic) | -$0.53 | -10.4% |
| EPS (Diluted) | -$0.53 | -10.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $33.2M | +119.3% |
| Short-term Investments | $202.5M | +11.8% |
| Current Assets | $241.6M | +19.5% |
| Total Assets | $253.4M | +19.1% |
| Current Liabilities | $20.4M | +38.5% |
| Long-term Debt | $29.9M | +12.4% |
| Total Liabilities | $50.3M | +21.4% |
| Stockholders' Equity |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$101.0M | -13.4% |
| Capital Expenditures | $22K | -12.0% |
| Investing Cash Flow | -$18.4M | +53.8% |
| Financing Cash Flow | $137.8M | +17.2% |
| Free Cash Flow | -$101.1M | -13.4% |
| $203.1M |
| +18.5% |